home > ict > winter 2020 > removing barriers for paediatric patients in clinical trials
International Clinical Trials

Removing Barriers for Paediatric Patients in Clinical Trials

Designed by Katemangostar / Freepik

As scientific breakthroughs in healthcare advance, our ability to discover and diagnose diseases earlier has renewed the need for paediatric research. However, there has been a growing tension between the need to license medication, strict regulations, and the recognised unprofitability of conducting trials in the paediatric population.

A major consideration in paediatric trials involves balancing the rights, safety, and well-being of children while meeting financial requirements to enable the production of safe, licensed medication. Perceived challenges in striking this balance may be a deterrent for some pharmaceutical companies.

Some of the key challenges include a lack of paediatric trials, leading to fewer licensed medications for children, misconceptions and mistrust participants may have in research, which may hinder participation in clinical trials, and how the industry may influence paediatric research through community education, with a hope that children will not be left behind as healthcare research continues to progress.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Evelyn Kamau is the Global Head of Nursing at the MRN and has over 20 years’ nursing experience. Evelyn has worked in critical care, haemodialysis and neurology centres both in the UK and her native country Kenya. Evelyn has been a lecturer for both undergraduate and postgraduate nursing students, a position that led her to the neurosurgery department at Cambridge University, where she was involved in pioneering research in the understanding and management of disorders of consciousness. She left Cambridge University to manage community-based trials at the MRN in 2016.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement